Epizyme, Inc. (EPZM): Andrew E. Singer , EVP & CFO of Epizyme, Inc. sold 1,013 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $10.36 per share for a total value of $10,493.97 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 7, 2016, Robert A Copeland (President of Research and CSO) sold 4,000 shares at $10.03 per share price.On Jun 10, 2016, Andrew E. Singer (EVP & CFO) sold 1,013 shares at $12.49 per share price.Also, On Mar 2, 2016, Peter Tai-ching Ho (Chief Development Officer) purchased 636 shares at $7.47 per share price.On Jan 12, 2016, Peter J Barris (10% owner) purchased 1,111,111 shares at $9.00 per share price.
Epizyme Inc: On Monday, Jul 11, 2016 heightened volatility was witnessed in Epizyme Inc which led to swings in the share price. The shares opened for trading at $10.4 and hit $10.49 on the upside , eventually ending the session at $10.35, with a gain of 0.39% or 0.04 points. The heightened volatility saw the trading volume jump to 2,06,942 shares. The 52-week high of the share price is $25.25 and the company has a market cap of $592 M . The 52-week low of the share price is at $8.27.
Company has been under the radar of several Street Analysts.Epizyme Inc is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 18 from a previous price target of $20 . The Rating was issued on May 10, 2016.
Epizyme Inc. is a clinical-stage biopharmaceutical company that discovers develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases or HMTs. The Company’s lead product candidate EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling and Phase I MLL-r pediatric patient trial enrolling.